References
- Keating M J, Smith T L, Kantarjian H, Cork A, Walters R, Trujillo J M, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
- Schiffer C A, Lee E J, Tomiyasu T, Wiernik P H, Testa J R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263–270
- Byrd J C, Mrozek K, Dodge R K, Carroll A J, Edwards C G, Arthur D C, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336
- Baer M R, Stewart C C, Lawrence D, Arthur D C, Byrd J C, Davey F R, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997; 90: 1643–1648
- Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, Grosset J M, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116: 834–838
- Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711–721
- Guerci A, Merlin J L, Missoum N, Feldmann L, Marchal S, Witz F, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85: 2147–2153
- Damiani D, Michelutti A, Michieli M, Masolini P, Stocchi R, Geromin A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol 2002; 116: 519–527
- Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, et al. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 2002; 87: 455–464
- Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
- Mitelman F. ISCN 1995: An international system for human cytogenetic Nomenclature 1995. S Karger, Basel, Switzerland 1995
- Del Poeta G, Venditti A, Stasi R, Aronica G, Cox M C, Buccisano F, et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leukemia Res 1999; 23: 451–465
- Haferlach T, Kern W, Schoch C, Schnittger S, Sauerland M CC, Heinecke A, et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004; 89: 408–418